# ABT Molecular Imaging

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abt-molecular-imaging

- Industry: Biotechnology
- Headquarters: Louisville, US
- Website: www.abt-mi.com
- Total disclosed funding: $16M
- Latest round: Series C (Sep 4, 2012)
- Investors on record: 5

## About

ABT Molecular Imaging, Inc. focuses on advancing medical imaging technology through innovative solutions like the B-100 Biomarker Generator, enhancing accessibility to Positron Emission Tomography (PET) diagnostics for healthcare facilities globally.Founded in 2006 and headquartered in Louisville, US, ABT Molecular Imaging specializes in medical imaging technology. The firm has undergone no significant pivots in its business strategy since its inception. Their latest funding round was in October 2014, where they raised USD 15 mn from SWK Holdings Corporation, totaling USD 15 mn in funding to date. The CEO is Peter Kingma.ABT Molecular Imaging specializes in medical imaging solutions, prominently featuring the B-100 Biomarker Generator, a compact device designed to produce unit doses of molecular imaging drugs for Positron Emission Tomography (PET) at the point of use. This innovation addresses accessibility to PET technology for over 65% of the global population and serves hospitals, research institutions, and diagnostic centers, especially in North America, Europe, and emerging markets.ABT's revenue generation is structured around the sale of its B-100 Biomarker Generator and associated services, including ongoing maintenance and support. The company engages primarily in B2B transactions, supplying medical facilities directly with its systems and establishing partnerships with research institutions to facilitate PET technology adoption. The transaction model includes one-time equipment purchases along with subscription-based or service agreements for continued support and supply of imaging drugs.ABT is focused on expanding its product line, with plans to enhance the B-100 Biomarker Generator and explore new offerings in medical imaging solutions. The recent funding of USD 15 mn will support these product development initiatives. Additionally, the company aims to penetrate new markets, particularly in Asia and South America, by 2016, enhancing its global footprint in the medical technology sector.

## Funding rounds

- Series C, Sep 4, 2012, $6M — Intersouth Partners, RC Capital, Council Capital, Mountain Group Partners, Council & Enhanced Tennessee Fund
- Series B, Jun 20, 2011, $4M — Intersouth Partners
- Series A, Sep 23, 2009, $6M — Intersouth Partners

## Investors

- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series A, Series B, Series C
- RC Capital (https://capitalatlas.ai/funds/rc-capital) — Series C
- Council Capital (https://capitalatlas.ai/funds/council-capital) — Series C
- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series C
- Council & Enhanced Tennessee Fund (https://capitalatlas.ai/funds/council-enhanced-tennessee-fund) — Series C